| INTRODUCTION
Vedolizumab, a humanised monoclonal antibody targeting a4b7 integrin, is effective as induction and maintenance therapy in patients with inflammatory bowel disease (IBD) in both clinical trials and clinical practice. [1] [2] [3] [4] [5] [6] Vedolizumab treatment leads to long-term mucosal healing, 7, 8 one of the major treatment targets in Crohn's disease (CD) and ulcerative colitis (UC). 9 The role of therapeutic drug monitoring in guiding therapeutic decisions in IBD patients treated with anti-tumour necrosis factor (TNF) agents is widely accepted. 10, 11 In vedolizumab-treated patients, there is evidence for an exposure-efficacy relationship during induction therapy. 12 We reported an association between low vedolizumab trough levels (< 19 lg/mL) during induction therapy and the need for additional doses of vedolizumab within 6 months. 13 In contrast with anti-TNF therapy, 14, 15 the correlation between vedolizumab trough levels during induction therapy and mucosal healing remains unknown.
The primary objective of our study was to investigate the relationship between early vedolizumab trough levels and mucosal healing within the first year of vedolizumab treatment in IBD patients.
Secondary objective was to identify potential factors associated with mucosal healing in this cohort.
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| Study design, patient population and definitions
In this observational study, we prospectively collected vedolizumab trough levels in all IBD patients at weeks 2, 6 and 14 of vedolizumab treatment in three French referral centres (Nancy, Lyon, Saint-Etienne) between 1 June 2014 and 31 March 2017. Only results of patients that underwent mucosal assessment between week 14 and week 52 after vedolizumab initiation were eligible for analysis. Ultimately, early vedolizumab trough levels in patients with and without mucosal healing within the first year after treatment initiation were compared.
Patients had to be 18 years or older at the time of study initiation. The use of immunosuppressive agents (azathioprine, methotrexate, 6-mercaptopurine) during vedolizumab induction therapy was allowed, but the dose had to be stable during a period of 2 weeks before until 14 weeks after the start of vedolizumab treatment.
Other exclusion criteria were a follow-up period of less than 14 weeks (due to a loss of follow-up, adverse events (infection, intolerance) or a lack of efficacity leading to a switch of treatment or surgery), lacking vedolizumab trough levels at weeks 2, 6 or 14 after treatment initiation, and the absence of mucosal assessment between week 14 and week 52 after the start of vedolizumab treatment.
Mucosal healing was prospectively assessed and defined as the absence of significant intestinal inflammation on magnetic resonance imaging (MRI) as judged by an experienced radiologist, and/or the absence of any ulcerations (for CD) or a Mayo subscore ≤1 (for UC) during endoscopy. In the overall population, a total number of 30 MRI examinations and 75 colonoscopies was performed during the study period.
| Patient management
Vedolizumab infusions (300 mg) were intravenously administered at weeks 0, 2 and 6 (induction phase), and then once every 8 weeks (maintenance phase). Treatment optimisation was possible from week 6 if necessary, and was done by increasing the dosing frequency to once every 4 weeks. The need for treatment optimisation was judged by the physician, based on clinical data and biochemical data such as C-reactive protein (CRP), according to routine practice. Also a lack of mucosal healing during maintenance phase could trigger treatment optimisation. Vedolizumab trough levels did not influence the decision to optimise treatment, as all the clinicians who took care of the enrolled IBD patients were blinded to the results of vedolizumab trough levels during the whole period of the study.
| Vedoluzimab trough levels and antibodies to vedolizumab
Vedolizumab was quantified using a specific biotinylated antibody directed against the idiotype of vedolizumab in an enzyme-linked immunosorbent assay following the manufacturer's protocol (Theradiag, Marne-la-Vall ee, France). This assay can measure vedolizumab trough levels ranging from 2 to 60 lg/mL. A bridging, drug-sensitive, enzyme-linked immunosorbent assay was used to quantify anti-drug antibodies (Theradiag, Marne-la-Vall ee, France). This assay ranges from 35 to 500 ng/mL. Biologists carrying out the analysis of vedolizumab trough levels were blinded to the clinical and endoscopic outcomes of vedolizumab-treated patients.
| Statistical analysis
All statistical analyses were performed using R, version 3. 
| Early vedolizumab trough levels and mucosal healing within 1 year after treatment initiation
Median vedolizumab trough levels in the overall population were 27 lg/mL (IQR 21.2-33.8 lg/mL) at week 2, 23 lg/mL (IQR 15-34.5 lg/mL) at week 6 and 10.7 lg/mL (IQR 4.6-20.4 lg/mL) at week 14 after the first infusion of vedolizumab. Corresponding means were 28.3 lg/mL (SD 11.61 lg/mL) at week 2, 26.2 lg/mL (SD 14.65 lg/mL) at week 6 and 12.4 lg/mL (SD 8.6 lg/mL) at week 14. There were no differences between patients with and without immunosuppressive therapy during this period, except for mean values at week 6 (Table S1 ). Only median vedolizumab trough levels at week 6 of vedolizumab treatment differed between patients with and without mucosal healing within the first year after treatment initiation (26.8 vs 15.1 lg/mL, P = 0.035) ( Table 2 ). The correlation between early vedolizumab trough levels and mucosal healing within the first year after treatment initiation for CD and UC patients separately can be found in Table S2 .
Only two patients (2.4%) had detectable antibodies against vedolizumab, one in the group with mucosal healing and one in the group without mucosal healing within the first year after treatment optimisation.
In the overall population, a cut-off trough level of 18 lg/mL at week 6 predicted mucosal healing within the first year after the start of vedolizumab with a sensitivity, specificity, accuracy, positive pre- Table 3 ).
| DISCUSSION
In this prospective, multicentre, observational study, we explored the correlation between early vedolizumab trough levels and mucosal healing with 1 year after treatment initiation. It is clearly established that anti-TNF trough levels during induction therapy correlate with mucosal healing in IBD. 14, 15 To the best of our knowledge, this trial is the first to confirm a similar relationship in vedolizumab-treated patients.
In a retrospective study comprising only IBD patients treated with vedolizumab for more than 1 year, mucosal healing was seen in 16 of 24 (44%) CD patients and in 20 of 34 (70%) UC patients at the last available colonoscopy. 8 Mucosal healing in our cohort was T A B L E 2 Early vedolizumab trough levels and mucosal healing within 1 year after vedolizumab initiation in the overall population and UC. In the overall population, vedolizumab trough levels at week 6 of treatment were higher in patients with mucosal healing compared to patients without mucosal healing within the first year after treatment initiation. We could not confirm any statistical significant differences between early vedolizumab trough levels when analysing CD and UC patients separately, possibly due to the lower number of patients in both subgroups. Nevertheless, the accuracy of a vedolizumab trough level of 18 lg/mL after 6 weeks of treatment to predict mucosal healing was comparable in patients with CD and UC. This is in line with a previous trial showing similar population pharmacokinetic parameters for vedolizumab in patients with moderately to severely active CD and UC. 16 Analogous to anti-TNF therapy, 10 it might therefore be assumed that cut-offs for therapeutic drug monitoring of vedolizumab-treated patients are the same in patients with CD and UC. However, whether higher cut-off vedolizumab trough levels are desirable in special situations such as perianal CD, as it has been described in infliximab-treated patients, 17 remains to be determined.
High vedolizumab trough levels are associated with higher clinical remission rates, with an imperative threshold of 17 lg/mL for CD and 16 lg/mL for UC at week 6 after treatment initiation to achieve higher clinical remission rates compared with placebo. 12 In a recent prospective study, we showed that vedolizumab trough levels below 19 lg/mL at week 6 of treatment were associated with the need for additional doses during the first 6 months of vedolizumab therapy. 13 In our cohort, we found a similar treshhold to predict mucosal healing. This contrasts with findings in infliximab-treated patients, where better targets require higher trough levels, 18, 19 although in adalimumab-treated patients this association is less clear.
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Patients with mucosal healing within the first year after vedolizumab initiation tended to have underwent less frequent dose optimisation compared to patients without mucosal healing. This can partly be explained because the lack of mucosal healing during maintenance phase could trigger treatment optimisation, even in the absence of clinical or biochemical abnormalities. We did not routineously perform vedolizumab trough levels after week 14 of treatment, so the impact of treatment optimisation to changes in vedolizumab trough levels and its correlation with treatment response could not be determined.
We found that there was no linear association between early vedolizumab trough levels and CRP, although logistic regression analysis showed lower trough levels of vedolizumab if CRP was above 5 mg/L. This might be explained by an increased clearance of the drug when CRP is high.
We coud not show any consistent benefit of combination therapy of vedolizumab with an immunosuppressor during the first 14 weeks of treatment. Combination therapy at initiation did not lead to higher early vedolizumab through levels, nor was it predictive of mucosal healing within the first year of treatment. These results are in line with our previous finding that addition of methotrexate neither restored clinical response nor improved the pharmacokinetic profile of vedolizumab-treated patients. 21 Potential explanation is the low immunogenicity of vedolizumab. In the GEMINI 1 study, 23 of 620 (3.7%) UC patients with available blood samples had samples that were positive for anti-vedolizumab antibodies at any time, and only six (1%) had persistently positive anti-vedolizumab antibodies. 1 Similarly, in the GEMINI 2 study, 33 of 814 (4.1%) CD patients had at least one sample positive for anti-vedolizumab antibodies at any time, and only three (0.4%) had two or more consecutive samples that were positive. 2 Prevalence of anti-vedolizumab antibodies was 2.2% in another trial using a drug resistant assay. 22 In our cohort, only two of 82 (2.4%) patients had detectable anti-vedolizumab antibodies, despite all anti-drug antibodies above the lower limit of detection (35 ng/mL) were characterised as positive.
To quantify vedolizumab trough levels, we used a specific biotinylated antibody directed against the idiotype of vedolizumab in an enzyme-linked immunosorbent assay following the manufacturer's protocol (Theradiag), as described earlier. 13 Others used an enzymelinked immunosorbent assay with a lower limit of quantification of 1.25 lg/mL at a 1:100 dilution, and an upper limit of 8 lg/mL in undiluted serum. Serums with vedolizumab levels higher than 8 lg/ mL had to be diluted until within the assay range. 12 This may contribute to discrepancy between cut-offs of vedolizumab trough levels that were identified across studies.
Strengths of our study are the multicentre design, the high number of included patients, the prospectively collection of vedolizumab trough levels at three different timepoints early in the treatment and the endpoint of mucosal healing. But there are also some limitations.
Endoscopists were not blinded to the treatment regimen of the 
